Blueprint Medicines’s Earnings Outlook
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here’s what investors…
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
Across the recent three months, 6 analysts have shared their insights on Blueprint Medicines (NASDAQ:BPMC), expressing a variety…
Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
Throughout the last three months, 8 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), offering a diverse set of opinions…
Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here’s What You Need To Know
Raymond James has decided to maintain its Strong Buy rating of Blueprint Medicines (NASDAQ:BPMC) and raise its price…
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Reported December 9, 2023, Blueprint Medicines Announced Data Showcasing Its Commitment To Advance The Scientific Understanding And Treatment Of Systemic Mastocytosis Was Highlighted At 2023 ASH Annual Meeting
-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership
The Latest Analyst Ratings for Blueprint Medicines
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: Bullish Somewhat Bullish Indifferent…
Needham Maintains Buy Rating for Blueprint Medicines: Here’s What You Need To Know
Needham has decided to maintain its Buy rating of Blueprint Medicines (NASDAQ:BPMC) and raise its price target from…
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here’s What You Need To Know
Barclays has decided to maintain its Equal-Weight rating of Blueprint Medicines (NASDAQ:BPMC) and raise its price target from…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 168.2% to $2.28 during Thursday’s regular session. As of 13:31…